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A tumor blood vessel is a key regulator of tissue perfusion, immune cell trafficking, cancer metastasis, and therapeutic
responsiveness. mTORC1 is a signaling node downstream of multiple angiogenic factors in the endothelium. However,
mTORC1 inhibitors have limited efficacy in most solid tumors, in part due to inhibition of immune function at high doses
used in oncology patients and compensatory PI3K signaling triggered by mTORC1 inhibition in tumor cells. Here we show
that low-dose RAD001/everolimus, an mTORC1 inhibitor, selectively targets mTORC1 signaling in endothelial cells (ECs)
without affecting tumor cells or immune cells, resulting in tumor vessel normalization and increased antitumor immunity.
Notably, this phenotype was recapitulated upon targeted inducible gene ablation of the mTORC1 component Raptor in
tumor ECs (RaptorECKO). Tumors grown in RaptorECKO mice displayed a robust increase in tumor-infiltrating lymphocytes
due to GM-CSF–mediated activation of CD103+ dendritic cells and displayed decreased tumor growth and metastasis.
GM-CSF neutralization restored tumor growth and metastasis, as did T cell depletion. Importantly, analyses of human
tumor data sets support our animal studies. Collectively, these findings demonstrate that endothelial mTORC1 is an
actionable target for tumor vessel normalization, which could be leveraged to enhance antitumor immune therapies.
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Introduction
A rapidly growing tumor requires blood vessels to support the increased demands for nutrients and oxygen. 
Cancer cells produce angiogenic factors that direct rapid blood vessel growth. However, unlike vessels in 
healthy tissues, tumor blood vessels are highly dysfunctional, characterized by chaotic networks of  leaky, 
tortuous, and uneven endothelial tubules without pericyte support (reviewed in refs. 1, 2). These vascular 
abnormalities cause sluggish blood flow, vascular leakiness, and poor perfusion in tumors. Given that many 
anticancer treatments are delivered to the tumor through the circulation, the inherently diminished func-
tion of  the tumor vasculature may limit drug delivery to tumors, thus diminishing the efficacy of  treatments 
(3). Further, immune responses and leukocyte trafficking may be affected by poor tumor perfusion, as well 
as by the hypoxic microenvironment created by the faulty vessels (4, 5). Constant vessel remodeling in 
tumors also contributes to spontaneous hemorrhage and increased interstitial fluid pressure, which blocks 
drug delivery and enhances a malignant tumor phenotype, including metastasis (6). As such, the abnor-
mal nature of  the tumor vasculature enhances tumor metastasis, immune escape, and poor therapeutic 
response. Traditional antiangiogenic therapy blocks tumor vessel growth, which can limit the growth of  
many tumors. However, the abolition of  angiogenesis further heightens hypoxia and interstitial pressure 
A tumor blood vessel is a key regulator of tissue perfusion, immune cell trafficking, cancer 
metastasis, and therapeutic responsiveness. mTORC1 is a signaling node downstream of multiple 
angiogenic factors in the endothelium. However, mTORC1 inhibitors have limited efficacy in most 
solid tumors, in part due to inhibition of immune function at high doses used in oncology patients 
and compensatory PI3K signaling triggered by mTORC1 inhibition in tumor cells. Here we show 
that low-dose RAD001/everolimus, an mTORC1 inhibitor, selectively targets mTORC1 signaling 
in endothelial cells (ECs) without affecting tumor cells or immune cells, resulting in tumor vessel 
normalization and increased antitumor immunity. Notably, this phenotype was recapitulated upon 
targeted inducible gene ablation of the mTORC1 component Raptor in tumor ECs (RaptorECKO). 
Tumors grown in RaptorECKO mice displayed a robust increase in tumor-infiltrating lymphocytes 
due to GM-CSF–mediated activation of CD103+ dendritic cells and displayed decreased tumor 
growth and metastasis. GM-CSF neutralization restored tumor growth and metastasis, as did T cell 
depletion. Importantly, analyses of human tumor data sets support our animal studies. Collectively, 
these findings demonstrate that endothelial mTORC1 is an actionable target for tumor vessel 
normalization, which could be leveraged to enhance antitumor immune therapies.
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within the tumor, thus enhancing the escape of  cancer cells via invasion and metastasis in animal models 
(7, 8). An emerging concept for improved therapy is to find ways to improve the functionality of, or to “nor-
malize,” tumor blood vessels (9–11). Vessel normalization increases vessel pericyte coverage, reduces vessel 
leakiness, improves tumor perfusion, and decreases tumor hypoxia.
Notably, recent evidence suggests that tumor vessel normalization may enhance infiltration of  the 
tumor parenchyma by leukocytes (1, 12–15), a discovery consistent with observations that blood vessels 
regulate leukocyte trafficking in different tissues (16, 17). Importantly, T cell exclusion from the tumor 
parenchyma limits tumor response to immunotherapy. Conversely, leukocytes within tumors may influence 
the integrity of  the tumor vasculature. For example, T helper type 1 (Th1) CD4+ T cells, M1-like tumor-as-
sociated macrophages (TAMs), and eosinophils each enhance tumor vessel normalization (13, 18, 19). This 
immune-vascular crosstalk suggests that tumor vessel normalization may contribute substantially to tumor 
immunology, particularly in the context of  immunotherapy.
The serine/threonine kinase mTOR is a central member of  a multi-subunit signaling complex that inte-
grates environmental cues to regulate proliferation, survival, and metabolic homeostasis in many cell types 
(20, 21). The importance of  mTOR signaling in tumor cells has been extensively studied (20, 21), but rela-
tively little is known about mTOR signaling in tumor blood vessels. The mTOR kinase acts in 2 functional-
ly distinct complexes with shared (e.g., mTOR and mTOR associated protein, LST8 homolog) and unique 
(e.g., Raptor in mTORC1, Rictor in mTORC2) components. mTORC1 phosphorylates several substrates 
involved in protein translation and cellular proliferation, including ribosomal protein S6 kinase-1 (S6K1). 
Interestingly, S6K1 knockdown in vascular endothelial cells (ECs) inhibits angiogenesis in vivo (22), sug-
gesting that signaling through the mTORC1 pathway might affect vascular ECs. Conversely, constitutively 
active S6K1 expression increases reactive oxygen species (ROS) generation and NADPH oxidase (NOX1 
and NOX2) mRNA levels in EC cultures (23). Further, aberrant mTORC1 activation in ECs promotes 
angiogenesis (24), driving formation and progression of  lymphangiosarcoma (25). Together, these studies 
implicate mTORC1 signaling in growth and/or homeostasis of  the tumor vasculature, but this hypothesis 
has not yet been tested in the context of  tumor vasculature.
In this report, we demonstrate that EC-specific deletion of  Raptor (RaptorECKO), a unique component 
of  mTORC1, caused tumor blood vessel normalization and decreased tumor growth and lung metastasis. 
Tumors with Raptor/mTORC1-deficient ECs harbored increased tumor-infiltrating lymphocytes (TILs) 
with enhanced cytotoxic T cell activation markers, increased CD103+ DCs, and elevated GM-CSF. In vivo 
neutralization of  either GM-CSF or T cells partially rescued phenotypes in RaptorECKO tumors, suggest-
ing that tumor growth inhibition was due, at least in part, to an enhanced GM-CSF–directed immune 
response. In human tumors, expression of  vessel normalization markers negatively correlated with endo-
thelial expression of  mTORC1/RAD001-sensitive genes, while GM-CSF levels positively correlated with 
markers of  immune cells, CD103+ DCs, and cytotoxic gene signature. Importantly, low-dose RAD001, 
an mTORC1 inhibitor, induced selective inhibition of  mTORC1 signaling in tumor ECs, promoted vessel 
normalization, increased TILs, and improved adoptive T cell therapy. Taken together, our findings suggest 
endothelial mTORC1 inhibition is a novel approach to normalize tumor blood vessels and enhance antitu-
mor immunity.
Results
Low-dose RAD001 selectively inhibits mTORC1 signaling in tumor endothelium and suppresses tumor growth. 
mTORC1 is a signaling node downstream of  multiple angiogenic factors. mTORC1 inhibitors are FDA 
approved but conventionally used at doses that are immunosuppressive. However, recent studies and clin-
ical trials discovered that low-dose mTORC1 inhibitors, such as RAD001/everolimus, inhibit mTORC1 
signaling but are not immunosuppressive (26, 27). To determine the effect of  low-dose RAD001 on tumor 
blood vessels and tumor growth, we implanted Lewis lung carcinoma (LLC) tumor cells containing expres-
sion of  hypoxia responsive element–driven (HRE-driven) mCherry and ovalbumin (OVA), referred to as 
LLC-HRE-mCherry-OVA, into C57BL/6 recipient mice (Figure 1A). Six days after LLC tumor implanta-
tion, mice were given RAD001 daily at 0.01 mg/kg or 0.05 mg/kg or vehicle control for 8 days, followed 
by adoptive transfer of  preactivated Thy1.1+ (OT-I) CD8+ and OT-II CD4+ T cells expressing the IFN-γ–
yellow fluorescent protein (YFP) reporter (28–30). Because T cells harvested from OT-I or OT-II trans-
genic mice express the T cell receptor (TCR) that specifically recognizes the OVA-derived peptide antigen 
bound to MHC-I or MHC-II, this approach allows for a detailed analysis of  tumor antigen–directed T cell 
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responses. As shown in Figure 1B, treatment with both low doses of  RAD001 significantly reduced tumor 
volume at day 18, 4 days after T cell adoptive transfer, indicating that low-dose RAD001 improved adoptive 
T cell therapy. Phospho–flow cytometry analysis revealed that low-dose RAD001 treatment inhibited p-S6, 
a downstream target of  mTORC1 signaling, in CD31+ ECs (Figure 1C), but not in CD45–CD31– popula-
tions (including tumor cells) and CD45+ immune cells (Figure 1D), suggesting that low doses of  RAD001 
primarily target ECs within the tumor microenvironment.
Loss of  Raptor/mTORC1 in ECs reduces tumor growth and metastasis. To investigate the role of mTORC1 in 
vascular ECs genetically, we crossed mice harboring floxed Raptor alleles (Raptorfl/fl, referred to as RaptorWT) 
with mice expressing tamoxifen-inducible Cre recombinase (CreER) under the control of the Cdh5/vascular 
endothelial-cadherin (VE-Cad) gene promoter, thus generating mice with inducible EC-specific loss of Raptor 
(referred to as RaptorECKO) following tamoxifen treatment (Supplemental Figure 1A; supplemental material 
available online with this article; https://doi.org/10.1172/jci.insight.139237DS1). RaptorECKO mice were via-
ble and healthy before and following tamoxifen treatment. Previous studies suggest that lung vascular ECs with 
Raptor knockout are viable and competently form tubules in culture (31), suggesting that Raptor/mTORC1 is 
not required for the survival of vascular ECs in adult animals.
To investigate the contribution of  mTORC1 specifically within tumor vasculature, we implanted LLC 
tumor nodules into tamoxifen-treated WT or RaptorECKO recipient mice and measured tumor size over a 
time course (Figure 2A). These LLC tumor nodules were propagated through serial in vivo transplantation 
and retained their ability to metastasize in 100% of  animals (32). Measurements of  tumor burden using 
bioluminescence (Figure 2B) or a caliper-based method (Figure 2C) demonstrated significantly decreased 
tumor growth in RaptorECKO mice as compared with controls. IHC measurements of  proliferating cell 
nuclear antigen revealed decreased tumor cell proliferation in RaptorECKO tumors (Supplemental Figure 
1B), while TUNEL analysis revealed increased tumor cell death (Supplemental Figure 1C). Lungs harvest-
ed at the study endpoint (~3 weeks after tumor implantation) were assessed for surface metastases, reveal-
ing substantially decreased metastases in RaptorECKO mice as compared with WT mice (Figure 2D). To rule 
out the influence of  tumor size on the metastatic potential of  tumors grown in RaptorECKO mice, we repeat-
ed these studies with a modified approach, removing primary LLC tumors when tumor volume reached 
500 mm3, and then assessed lung metastasis 12 days following tumor resection (Supplemental Figure 1D). 
Figure 1. Low-dose RAD001 selectively inhibits mTORC1 signaling in tumor endothelium and suppresses tumor growth. (A) Schematic diagram showing the 
experimental design with LLC-HRE-mCherry-OVA tumor cell implantation, RAD001 treatment, adoptive T cell transfer, and EF5 intravenous injection.  
(B) Growth curves of LLC-HRE-mCherry-OVA tumors treated with a low dose of RAD001. n = 14–16 mice per group. P values were determined by Student’s t 
tests comparing vehicle- and RAD001-treated groups at day 18. (C and D) Flow cytometric analysis showing low-dose RAD001 treatment decreased p-S6 level 
in CD45–CD31+ tumor-associated ECs (C) but not in LLC tumor cells (CD45–CD31–) and immune cells (CD45+) (D). MFI, mean fluorescence intensity. All data are 
presented as mean ± SD, and P values were determined by 1-way ANOVA with post hoc Tukey’s correction for multiple comparisons. **P ≤ 0.01, *P ≤ 0.05.
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Measurements of  lung bioluminescence (Supplemental Figure 1, E and F), as well as counting of  lung 
surface metastatic lesions (Supplemental Figure 1G), showed a diminished burden of  lung metastases in 
RaptorECKO mice as compared with controls. These studies confirm that mTORC1 signaling within tumor 
vasculature supports tumor cell growth, survival, and metastasis.
To complement tumor allograft studies, we analyzed the EC-specific Raptor/mTORC1 loss in the 
transgenic MMTV-PyMT spontaneous mammary tumor model (33), using RaptorECKO mice crossed with 
MMTV-PyMT mice (RaptorECKO PyMT). At 8 weeks of  age, female RaptorWT PyMT and RaptorECKO PyMT 
mice were treated with tamoxifen to induce irreversible Raptor loss from vascular ECs. Tumor burden was 
monitored weekly beginning at 18 weeks of  age. Notably, mammary tumor latency was delayed (Figure 
2E), while tumor growth was markedly reduced (Figure 2F) in tamoxifen-treated RaptorECKO PyMT mice as 
compared with tamoxifen-treated controls. Further, lung metastasis was significantly inhibited in 28-week-
old tamoxifen-treated RaptorECKO PyMT mice as compared with age-matched controls (Figure 2G). These 
data confirm findings using the LLC allografted tumor model and suggest that Raptor/mTORC1 loss from 
tumor blood vessels inhibits tumor growth and lung metastasis.
Selective inhibition of  mTORC1 in ECs decreases angiogenic sprouts and normalizes tumor blood vessels. To deter-
mine the impact of  Raptor/mTORC1 on tumor vasculature, we first assessed tumor microvessel density and 
morphology in situ using CD31 and smooth muscle actin (α-SMA), a pericyte marker, to visualize ECs in 
low-dose RAD001–treated LLC-HRE-mCherry-OVA tumors (Figure 3A). Treatment with low-dose RAD001 
(0.01 mg/kg) reduced the density of  CD31+ tumor vessels (Figure 3B) and induced an increase in pericyte 
Figure 2. Raptor/mTORC1 loss in tumor endothelium decreases tumor growth and metastasis. (A) Schematic diagram showing the experimental procedure 
of tamoxifen treatment and subcutaneous implantation of LLC tumor nodules. (B) Representative image of bioluminescence signal from LLC tumors on WT 
control and RaptorECKO mice. (C) Growth curves of LLC tumors on WT control and RaptorECKO mice. Tumors were measured by a caliper every other day from day 
10 through 20 after tumor implantation. n = 12 to 15 mice per group. **P ≤ 0.01, 2-way ANOVA. (D) Representative images of the lungs harvested from WT 
and RaptorECKO mice after 20 days of LLC tumor implantation. Arrows indicate metastatic foci on the surface of lungs, which were quantified. (E) Disease-free 
survival of spontaneous MMTV-PyMT tumors against age (weeks). n = 22 to 28 mice per group. **P ≤ 0.01. Statistical analysis was performed using log-rank 
test. (F) Growth curves of spontaneous MMTV-PyMT tumors on WT control and RaptorECKO mice. **P ≤ 0.01, 2-way ANOVA. (G) Representative H&E staining 
of lungs harvested from WT and RaptorECKO/MMTV-PyMT mice. Arrows indicate metastatic foci within the lungs, which were quantified. Scale bar: 200 μm. 
Unless indicated, all data are presented as mean ± SD, and P values were determined by 2-tailed unpaired Student’s 2-tailed t test. **P ≤ 0.01.
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coverage of  tumor vessels, as measured by CD31/α-SMA costaining in tumors (Figure 3C), indicating an 
improvement in vessel maturation. Further, measurements of  tumor hypoxia using the HRE-mCherry report-
er (34) revealed that mCherry expression (Figure 3, D and E) was decreased in LLC-HRE-mCherry-OVA 
tumors after low-dose RAD001 treatment, and reduced hypoxia was confirmed by the staining of  a hypoxic 
marker, EF5, on tumor cells (Figure 3F). Taken together, these data suggest that low-dose RAD001 preferen-
tially inhibits mTORC1 signaling in ECs, leading to an increase in tumor vessel normalization.
To verify the role of  endothelium-specific mTORC1 in vessel normalization, we next accessed tumor 
vasculature in LLC tumors grown on RaptorWT and RaptorECKO mice. Consistent with our finding in low-
dose RAD001 treatment, the density of  CD31+ tumor vessels was decreased in tumors after Raptor/
mTORC1 was deleted in vessels (Figure 3G). Morphometric analyses of  vascular lumen area revealed 
increased lumen size of  RaptorECKO tumor vessels compared with RaptorWT tumor vessels (Figure 3H), con-
sistent with the morphology of  normalized blood vessels. In line with this observation, pericyte coverage of  
tumor vessels was increased in RaptorECKO tumors relative to WT tumors (Figure 3I). Further, perfusion of  
vasculature was increased in RaptorECKO tumors, as revealed by lectin perfusion assays (Figure 3J). Impor-
tantly, tumor cells expressing hypoxia-induced mCherry localized in areas distant from CD31+ vessels and 
mCherry+ intensity were significantly reduced in RaptorECKO samples as compared with RaptorWT samples 
(Figure 3K), suggesting increased perfusion and oxygen delivery by vessels lacking mTORC1 signaling. 
However, loss of  Raptor in tumor-free endothelium did not significantly change CD31+ vessel intensity 
or α-SMA+ pericyte coverage in normal tissues (Supplemental Figure 2, A–D), indicating that mTORC1 
signaling is preferentially required for tumor endothelium.
Low-dose RAD001 treatment increases the numbers and effector functions of  TILs. Functional vascular net-
works govern immune cell trafficking in untransformed tissues (17). Given that endothelial Raptor loss or 
mTORC1 inhibition improved vascular function within the tumor microenvironment, we next assessed 
leukocyte infiltration in LLC-HRE-mCherry-OVA tumors after low-dose RAD001 treatment (Figure 4A). 
Against the dogma of  immune-suppressive function of  RAD001, 0.01 mg/kg RAD001 low-dose treatment 
increased the numbers of  infiltrating total CD45+ leukocytes and TCRβ+ T cells (Figure 4, B and C), con-
sistent with its positive effect on vessel normalization (Figure 3, A–C). Importantly, there was a significant 
increase in numbers and effector function of  adoptively transferred donor OT-I CD8+ T cells, as measured 
by percentages of  OT-I CD8+ T cells (Figure 4D) and YFP+Thy1.1+CD8+ cells (Figure 4E), respective-
ly (donor T cells expressing an IFN-γ–YFP reporter, refs. 28–30). Low-dose (0.01 mg/kg) RAD001 also 
enhanced infiltration of  Thy1.1+CD4+ donor T cells (Figure 4F) and their activity, with an increase in YFP+ 
(IFN-γ+) Thy1.1+CD4+ T cells (Figure 4G). Together, these data suggest that low-dose RAD001 increases 
TILs and enhances effector function of  adoptively transferred T cells.
Loss of  endothelial Raptor/mTORC1 increases TILs and enhances cytotoxic effector functions of  CD8+ T cells. To 
verify the impact of  endothelial mTORC1 on tumor immune response, we next performed a tumor size–
matched experiment by implanting LLC tumors in tamoxifen-naive RaptorWT or RaptorECKO mice and grow-
ing tumors for 8 days, at which point tamoxifen was administered to induce CreER activity within vascular 
ECs (Supplemental Figure 3A). Tumors were harvested 10 days after initial tamoxifen treatment (Figure 5A), 
when tumor weight was not significantly different between WT and RaptorECKO mice (Figure 5B). Consis-
tent with our finding in RAD001-treated mice (Figure 4B), significantly increased CD45+ leukocyte popula-
tions were observed from tumors grown in tamoxifen-treated RaptorECKO tumors (Figure 5C). More detailed 
immunophenotyping of  tumor leukocyte populations revealed no consistent changes in the proportion of  
CD19+ B cells, F4/80+ macrophages, CD11b+Ly6G+ myeloid cells, NK cells, or CD4+CD25+FoxP3+ regula-
tory T cells associated with loss of  Raptor from tumor ECs (Supplemental Figure 3C). Analysis of  the tumor 
CD3+ T cell populations revealed that proinflammatory CD8+IFN-γ+ T cells were significantly increased in 
RaptorECKO tumors (Figure 5D), and CD4+IFN-γ+ T helper cells were moderately increased (Supplemental 
Figure 3E). These data suggest that Raptor/mTORC1 loss from tumor ECs increases TILs, particularly those 
expressing proinflammatory markers. Therefore, mTORC1-mediated activity contributes to tumor vessel dys-
function, which in turn may alter the recruitment and phenotype of  TILs.
To test whether our findings apply to other tumor types, we used allografted MMTV-PyMT mouse mam-
mary tumor cells engineered to express OVA, referred to as PyMT-OVA (Figure 5E). PyMT-OVA tumors were 
implanted into the tamoxifen-naive RaptorECKO or RaptorWT mice. Four days following tumor implantation, 
mice were treated with tamoxifen to delete Raptor expression in the endothelium, followed by adoptive transfer 
of preactivated OT-I CD8+ T cells at day 10, and tumors were collected on day 14 (Supplemental Figure 3B and 
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Figure 3. Selective inhibition of mTORC1 in endothelium normalizes tumor blood vessels. (A) Representative images of CD31+ (shown in green, 
EC marker) and α-SMA (shown in magenta, pericyte marker) costaining in LLC-HRE-mCherry-OVA tumors treated with low-dose RAD001. Arrows 
indicate colocalization of CD31+ and α-SMA. Scale bar: 100 μm. (B) Tumor vessel density was quantified as CD31+ area/field in LLC-HRE-mCherry-
OVA tumors. (C) Pericyte coverage on tumor blood vessels was quantified and presented as percentage of α-SMA+CD31+ vessels. (D) Representative 
images of mCherry expression (red) in LLC-HRE-mCherry-OVA tumors treated with low-dose RAD001. Tumor vessels were assessed by CD31 staining 
(green). Arrows indicate mCherry+ hypoxic area. Scale bar: 50 μm. (E and F) Hypoxic regions in LLC-HRE-mCherry-OVA tumors were quantified by flow 
cytometry to assess the fluorescence intensity of mCherry+ (E) and EF5+ (F) in CD45– tumor cells after RAD001 treatment. (G) Representative images 
and quantification of CD31+ blood vessels (red) in LLC tumors harvested from WT control and RaptorECKO mice. n = 5–7 mice per group. Scale bar: 
100 μm. (H) Representative images and quantification of lumen size of CD31+ vessels from WT and RaptorECKO tumors. Zoomed-in images (original 
magnification, ×20) of dotted-line area are shown at the bottom. White solid lines mark lumen area in CD31+ vessels. n = 3 mice per group. Scale bar: 
100 μm. (I) Costain of CD31+ (red) and α-SMA (green) in LLC tumors from WT control and RaptorECKO mice. Arrows indicate colocalization of CD31 and 
SMA. Pericyte coverage on tumor blood vessels was quantified and presented as percentage of α-SMA+CD31+ vessels. n = 3–4 mice per group. 
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Figure 5F). Flow cytometric analysis and immunofluorescent detection of OT-I CD8+ T cells (gated or stained 
as CD45.1+) in PyMT-OVA tumors demonstrated a marked increase in tumor antigen–specific, exogenously 
delivered OT-I CD45.1+CD8+ T cells within the tumor parenchyma of PyMT-OVA tumors grown in RaptorECKO 
mice (Figure 5, G and H). Further, proinflammatory CD8+IFN-γ+ T cells were increased in PyMT-OVA tumors 
grown in RaptorECKO mice (Figure 5I), as were CD8+Granzyme B+ (GZMB) T cells (Figure 5J). Several other 
leukocyte populations occurred with similar frequency in RaptorWT and RaptorECKO tumors, although CD4+ T 
cells were moderately increased in RaptorECKO samples (Supplemental Figure 3, D and F). Together, these data 
suggest that loss of mTORC1 signaling within the tumor vasculature may permit greater TIL infiltration by T 
cells harboring proinflammatory markers, including those T cells specifically directed toward tumor antigens.
Because loss of  Raptor/mTORC1 increased proinflammatory CD8+IFN-γ+ T cells (Figure 5D) and 
CD4+IFN-γ+ T helper cells (Supplemental Figure 3E) in LLC tumors, we next determined whether T lympho-
cytes contribute to tumor suppression seen in RaptorECKO mice. LLC tumor–bearing mice were treated with 
multiple doses of  anti-CD4 or anti-CD8 neutralizing antibodies, the combination of  anti-CD4/anti-CD8 anti-
bodies, or with isotype-matched control IgGs (Figure 5K). Consistent with our finding in Figure 2C, tumors 
in IgG-treated RaptorECKO mice grew at a substantially reduced rate as compared with tumors in IgG-treated 
RaptorWT mice (Supplemental Figure 3G). Despite reduction of  CD8+ T cells by anti-CD8 antibody treatment 
(Supplemental Figure 3H), tumor growth in either RaptorWT or RaptorECKO mice was similar upon CD8 deple-
tion as compared with what was seen in IgG-treated tumors (Supplemental Figure 3G). Similarly, anti-CD4 
antibody alone did not significantly influence tumor growth in RaptorECKO mice, although CD4+ T cells were 
neutralized (Supplemental Figure 3, I and J). Interestingly, the combined depletion of  CD8 and CD4 together 
partially restored tumor growth (Figure 5, L and M), suggesting that T lymphocytes, at least in part, play 
a major role in limiting tumor growth in RaptorECKO mice. These data support the hypothesis that vascular 
mTORC1 inhibition enhances tumor infiltration by T cells, which actively limit tumor growth.
Endothelial Raptor/mTORC1 deficiency upregulates GM-CSF in RaptorECKO tumors. To determine potential 
molecular mechanisms by which endothelial Raptor/mTORC1 may dysregulate TIL activity, LLC tumor 
lysates from RaptorECKO mice and their RaptorWT sex-matched littermate controls (6 KO-WT pairs) were 
screened for cytokine and chemokine production by Luminex multiplex assay (Figure 6A). Of 32 tested 
cytokines/chemokines (Supplemental Table 1), GM-CSF was significantly elevated in RaptorECKO tumors 
across all 6 littermate pairs of  WT and RaptorECKO tumors (Figure 6B). ELISA on independent tumor lysates 
revealed a nearly 5-fold increase in GM-CSF protein levels in RaptorECKO tumors compared with RaptorWT 
tumors, confirming elevated GM-CSF protein levels in tumors grown in mice lacking vascular Raptor/
mTORC1 (Figure 6C). GM-CSF, among other functions, is known to stimulate DCs, promoting antigen 
presentation by DCs to both B and T cells (35). Indeed, GM-CSF has been used as an adjuvant to enhance 
vaccine efficacy in clinical trials to promote antitumor immunity in melanoma and pancreatic cancer (36, 
37). Among the many subtypes of  DCs, tumor-resident CD103+ DCs support T cell priming and effector 
T cell trafficking (38–40). Consistent with these findings, the percentage of  DCs that were CD103+ was 
significantly elevated in LLC tumors (Figure 6D) and MMTV-PyMT-OVA tumors (Figure 6E) grown in 
RaptorECKO mice, as well as in LLC-OVA tumors treated with 0.01 mg/kg of  RAD001 (Figure 6F), though 
no consistent changes in the overall numbers of  MHC-II+CD11c+ DCs were seen in tumors grown in WT 
and RaptorECKO mice or treated with vehicle and a low dose of  RAD001.
To determine if  increased CD103+ DCs are dependent on elevated GM-CSF in RaptorECKO mice, 
LLC tumors were implanted into tamoxifen-treated mice, and the tumor-bearing mice were treated with 
GM-CSF neutralizing antibodies or isotype-matched control IgG (Figure 6G). Depletion of  GM-CSF par-
tially restored defects of  tumor growth (Figure 6, H and I) and lung metastasis in RaptorECKO mice (Figure 
6J), compared with RaptorECKO animals treated with IgG control. Importantly, GM-CSF depletion signifi-
cantly reduced tumor-infiltrating CD103+ DCs in RaptorECKO mice with no changes in the total CD11c+ 
DCs (Figure 6K). Anti–GM-CSF also decreased the percentage of  IFN-γ+CD8+ T cells (Figure 6L) in Rap-
torECKO tumors. Taken together, these results suggest that GM-CSF is required for increased CD103+ DCs 
and enhanced cytotoxic CD8+ T cell activity in RaptorECKO tumors.
Scale bar: 100 μm. (J) Representative images showing lectin perfusion (green) in CD31+ tumor blood vessels (red). Arrows indicate lectin-perfused 
functional blood vessels. Vessel perfusion was quantified and presented as percentage of Lectin+CD31+/total CD31+ vessels. n = 5 mice per group. 
Scale bar: 100 μm. (K) Hypoxia was assessed by mCherry expression (red) in WT control and RaptorECKO tumors and quantified as mCherry+ intensity 
within tumors. n = 5–6 mice per group. Scale bar: 50 μm. AU, arbitrary units. All data are presented as mean ± SD. **P ≤ 0.01. *P ≤ 0.05, Student’s 
2-tailed t test.
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Analysis of  mTORC1 signaling, vessel normalization, GM-CSF, and immune markers in human cancer 
data sets. Because our data suggested that endothelial mTORC1 signaling is a key regulator of  vas-
cular dysfunction in tumors, contributing to tumor growth and immune evasion, we assessed possi-
ble correlations that may exist between a vessel normalization gene signature and mTORC1-mediated 
gene signatures using single-cell RNA-Seq data derived from patients with non–small cell lung can-
cer (NSCLC) or triple-negative breast cancer (TNBC) (41, 42). We focused on tumor-associated ECs 
that were already defined in these studies and performed single-sample gene set enrichment analysis 
(ssGSEA). Enrichment scores of  endothelial PDGFB and TEK/Tie2, 2 genes known to regulate recruit-
ment and proper integration of  pericytes to blood vessels (15, 43, 44), were used as a vessel normaliza-
tion signature. mTORC1 activity was assessed by using the mTORC1 pathway gene set (REACTOME) 
and the RAD001-sensitive gene set (CREIGHTON, which is defined as those that are upregulated 
upon overexpression of  AKT and subsequently downregulated by RAD001, an mTORC1 inhibitor) 
listed in Supplemental Table 2. Analyses of  correlations between the vessel normalization signature 
and the mTORC1-mediated signaling pathway gene set revealed that ECs with higher mTORC1 activity 
express fewer vessel normalization markers in both NSCLC (Figure 7A) and TNBC tumors (Figure 
7B). Consistently, expression of  RAD001-sensitive genes also negatively correlated with the expression 
of  normalization markers PDGFB and TEK in these ECs. These findings suggest that lower endothelial 
mTORC1 activity correlates with vessel normalization in human cancer.
Figure 4. Low-dose RAD001 increases the numbers and effector function of infiltrating T lymphocytes. (A) Schematic diagram showing the experimen-
tal design with LLC-HRE-mCherry-OVA tumor cell implantation, RAD001 treatment, and adoptive T cell transfer. (B and C) Representative flow cytometric 
plots and quantification of tumor-infiltrating CD45+ immune cells (B) and TCRβ+ T cells (C) in LLC tumors treated with low-dose RAD001. (D and E) Repre-
sentative flow cytometric plots and quantification of Thy1.1+CD8+ (D) and CD8+YFP+ (IFN-γ+) (E) donor T cells in LLC tumors treated with low-dose RAD001. 
(F and G) Representative flow cytometric plots and quantification of Thy1.1+CD4+ (F) and CD4+YFP+ (IFN-γ+) (G) donor T cells in LLC tumors treated with 
low-dose RAD001. All data are presented as mean ± SD. **P ≤ 0.01. *P ≤ 0.05, Student’s 2-tailed t test.
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Given our finding that upregulation of  GM-CSF in RaptorECKO tumors increased the proportion 
of  CD103+ DCs and IFN-γ+CD8+ T cells, we next examined if  GM-CSF has an impact on antitumor 
immunity in clinical lung (n = 1129) and breast cancer (n = 1218) data sets curated by The Cancer 
Genome Atlas (TCGA). Using PTPRC (CD45) gene expression as a proxy for total tumor leukocyte 
content, we identified a positive correlation between CSF-2 (GM-CSF) and CD45 in both lung and 
breast cancer patients (Figure 7C). To assess the level of  cytotoxic immune cell activity in tumors, we 
averaged expression of  3 genes, IFN-γ (IFNG), GZMB, and perforin (PRF1), as a cytotoxic signature, 
similar to what was described previously (45, 46). Notably, higher CSF-2 (GM-CSF) expression in both 
human lung and breast cancer samples positively correlated with the cytotoxic gene signature (Figure 
7D). Further, CD103+ DCs are a distinct DC population that is uniquely dependent on IRF8 and 
Figure 5. Raptor/mTORC1 loss in endothelium increases the numbers and effector function of tumor-infiltrating T cells. (A) Schematic diagram of 
experimental design with LLC tumor allograft. (B) Tumor weight at day 18 after implantation. Each dot represents a mouse. (C and D) Flow cytometric 
analysis of CD45+ (C) and IFN-γ+CD8+ (D) immune cells in WT and RaptorECKO tumors. (E) Schematic diagram of experimental design in MMTV-PyMT-
OVA tumor orthotopic allograft. (F) Tumor weight at day 14 after implantation. (G) Flow cytometric analysis of donor (CD45.1) and recipient (CD45.2) 
CD45+ immune cells in WT and RaptorECKO tumors. Donor CD45.1+ cells were quantified and shown on the right. (H) Immunofluorescence images of 
CD45.1 (green) CD8 OT-I donor T cells costained with CD31 (red) in PyMT tumors. Numbers of CD45.1+ cells were quantified. Arrows indicate CD45.1+ 
donor T cells in the LLC tumor. Scale bar: 100 μm. (I and J) Flow cytometric analysis of IFN-γ (I) and GZMB (J) in CD8+ T cells in WT and RaptorECKO 
PyMT-OVA tumors. (K) Schematic diagram of experimental design in LLC tumors treated with anti-CD4 and anti-CD8 neutralizing antibodies. (L) 
Growth curves of LLC tumors on WT control and RaptorECKO mice after T cell depletion. n = 3–7 mice per group. Two-way ANOVA. (M) T cell depletion 
was confirmed by flow cytometric analysis. Unless indicated, all data are presented as mean ± SD. **P ≤ 0.01. *P ≤ 0.05, Student’s 2-tailed t test.
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Batf3 transcription factors and predominantly expresses CCR7 in human tumors, expression of  which 
was used as a molecular proxy for CD103+ DCs in clinical tumor gene expression data sets (47, 48). 
Our analysis revealed a positive correlation between CSF-2 (GM-CSF) and IRF8, BATF3, or CCR7 in 
both lung and breast cancer patient cohorts (Figure 7E). Taken together, these findings suggest strong 
links between EC/mTORC1 signaling and vessel normalization and between GM-CSF and antitumor 
immunity in human cancers.
Figure 6. GM-CSF is required for increase in CD103+ DCs and IFN-γ+CD8+ T cells in RaptorECKO tumors. (A) Heatmap showing relative expression lev-
els of indicated chemokines/cytokines in LLC tumors harvested from 6 sex-matched littermate pairs of WT and RaptorECKO mice. Red indicates high-
er expression while green indicates lower expression in RaptorECKO tumors over WT control. (B) Quantification of GM-CSF expression in RaptorECKO 
tumors and WT control tumors from Luminex analysis. (C) GM-CSF ELISA on independent LLC tumor lysates to verify elevated GM-CSF expression 
in RaptorECKO tumors. n = 8 mice per group. (D–F) Flow cytometric analysis of CD11b+, CD11b+CD11c+, or CD11c+ immune cells and CD103+ DCs in WT and 
RaptorECKO tumors from the LLC model (D) and PyMT model (E) or in LLC-HRE-mCherry-OVA tumors treated with low-dose RAD001 (F). (G) Sche-
matic diagram showing the experimental procedure with GM-CSF neutralizing antibody treatment in the LLC model. (H) Representative image of 
bioluminescence signal from LLC tumors on RaptorECKO mice treated with anti–GM-CSF or IgG control on day 20 postimplantation. (I) Growth curves 
of LLC tumors on WT mice treated with IgG and RaptorECKO mice treated with anti–GM-CSF or IgG isotype antibodies. n = 8–11 mice per group. **P 
≤ 0.01. Two-way ANOVA. (J) Quantification of metastatic foci on the surface of lungs harvested in I. (K and L) Flow cytometric analysis of CD11b+, 
CD11b+CD11c+, or CD11c+ immune cells and CD103+CD11c+ DCs (K) and IFN-γ+CD8+ T cells (L) in tumors treated with IgG control and tumors treated with 
anti–GM-CSF. Unless indicated, all data are presented as mean ± SD. **P ≤ 0.01. *P ≤ 0.05, Student’s 2-tailed t test.
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Discussion
Tumor blood vessel normalization has been increasingly recognized to play critical roles in improving tissue 
perfusion, decreasing tumor hypoxia, and reducing vessel leakage, which lead to better drug delivery, improved 
antitumor immunity, and inhibition of tumor metastasis (11, 49). The mechanisms of vessel normalization, 
however, are not completely understood, such that actionable molecular targets for therapeutic tumor nor-
malization remain elusive. Here we report the discovery that Raptor/mTORC1 knockout in vascular ECs 
decreases tumor hypoxia, growth, and metastasis through vessel normalization. Interestingly, EC-specific Rap-
tor/mTORC1 loss also enhanced recruitment and activation of TILs, in part through GM-CSF–dependent 
activation of CD103+ DCs. Further, analyses of clinical tumor gene expression data sets demonstrated a neg-
ative correlation between vascular normalization markers and mTORC1 target gene signatures and a positive 
correlation between GM-CSF levels and molecular markers of T cell and DC activation. Notably, mTORC1 
inhibition using low-dose RAD001 normalized tumor blood vessels, increased TILs, and improved adoptive 
T cell therapy. Although further studies are necessary to investigate whether tumor blood vessel normalization 
plays a causal role in the enhanced antitumor immunity in our model systems, these studies demonstrate that 
endothelial mTORC1 is an actionable target for tumor vessel normalization, which could offer supportive ther-
apy for both traditional cancer treatments and emerging immunotherapies.
It is well accepted that T lymphocytes play a critical role in mediating antitumor immunity. The fact 
that depletion of  T lymphocytes partially reversed the phenotype in RaptorECKO mice supported our model 
Figure 7. Correlations between vessel normalization markers and mTORC1-mediated signaling, as well as GM-CSF and immune markers in human 
tumor samples. (A and B) Correlation between vessel normalization markers and mTORC1-mediated signaling using non–small cell lung cancer (NSCLC, 
GSE127465) (A) or triple-negative breast cancer (TNBC, GSE118390) (B) scRNA-Seq data sets. The x and y axes represent ssGSEA enrichment scores of 
indicated gene sets in ECs. Each point represents a single EC. (C and D) Correlations between CSF-2 (GM-CSF) transcript levels and levels of an immune cell 
marker PTPRC (CD45) (C) and a cytotoxic activity signature (an average expression of IFNG, GZMB, and PRF1) (D) in lung tumors (top) and breast tumors 
(bottom). (E) Correlations between CSF-2 (GM-CSF) transcript levels and levels of BATF3, IRF8, and CCR7 in lung tumors (top panels) and breast tumors 
(bottom panels). BATF3, IRF8, and CCR7 are “signature genes” for the human CD103+ DC population. The x and y axes are log2(mRNA) expression using 
the Lung Cancer (LUNG) data set (n = 1129) and the Breast Cancer (BRCA) cohort (n = 1218) from TCGA. Each dot represents a single tumor sample. Pearson 
correlation coefficient (r) and 2-tailed P values are shown. 
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that inhibition of  mTORC1 signaling in vascular ECs enhances antitumor immune response through a T 
cell–dependent mechanism (Figure 4 and Figure 5). The mechanisms by which tumor vessel normalization 
enhances TIL infiltration are likely to be mediated through chemokines and adhesion molecules, such as 
CXCL9/10 and ICAM1/E-selectin, respectively (13, 17, 50). Increased perfusion in normalized vessels 
could also take oxygen and nutrients (e.g., glucose and amino acids) into the tumor microenvironment 
for optimal T cell activation and effector function (51, 52). Further, tumor metabolites such as lactate 
and fatty acid have been shown to induce T cell apoptosis, inhibit effector T cell function, and induce 
M2 macrophage polarization (51, 52). More efficient removal of  these metabolites by normalized vessels 
would release the inhibition of  T cell function imposed by these tumor metabolites. Thus, our finding that 
mTORC1 inhibition within tumor vessel ECs supports tumor vessel normalization provides a foundation 
on which to begin studying these questions.
We show that Raptor/mTORC1 loss in endothelium leads to increased GM-CSF, which enhances 
antitumor immunity (Figure 6). However, GM-CSF has a dichotomous role in antitumor immunity. As 
a hematopoietic growth factor, GM-CSF controls the differentiation of  the myeloid lineage and functions 
as an immunomodulator to stimulate DC maturation and granulocyte/macrophage activity. Studies on 
preclinical models show that GM-CSF increases exogenous antigen presentation capacity of  CD103+ DCs 
(53–55) and promotes M1 macrophage polarization and T cell activation (56). Mice lacking GM-CSF or 
its receptor fail to establish protective immunity against a range of  microbes and self-antigens (57–59). In 
this context, GM-CSF has been used as a cancer vaccine adjuvant to enhance the recruitment, maturation, 
and function of  DCs in preclinical models and human clinical trials (35–37, 60, 61). In contrast to its 
immune-promoting roles, GM-CSF derived from tumors has been reported to drive the development of  
myeloid-derived suppressor cells (MDSCs) that suppress antitumor T cell functions (62, 63). In our system, 
RaptorECKO increased GM-CSF expression and CD11c+CD103+ DC infiltration in tumors (Figure 6, A–E) 
but did not consistently increase the infiltration of  CD11b+Ly6G+ (Gr1+) cells, a population commonly 
defined as MDSCs, in the tumor microenvironment (Supplemental Figure 3, C and D), suggesting that the 
primary role of  GM-CSF in RaptorECKO tumors is to promote CD103+ DC functions.
The tumor microenvironment (TME) is a diverse landscape, containing a variety of  cell types, 
including tumor cells, immune cell populations (lymphocytes, macrophages, NK cells, DCs, MDSCs), 
fibroblasts, and ECs, among others (64, 65). The current study focuses on T cells and CD103+ DCs, but 
we cannot exclude the possibility that other immune populations, such as NK cells, may also play a role 
in the antitumor immune response in RaptorECKO tumors. Loss of  endothelial Raptor/mTORC1 led to an 
increase in infiltrating NK and CD11b+Ly6G+ myeloid cell populations in LLC tumors (Supplemental 
Figure 3C). In addition to their intrinsic cytotoxic activity, NK cells have also been shown to produce 
CCL5 and XCL1 to recruit conventional DC1s, which express CD103+, to promote antitumor immunity 
(66). CD11b+Ly6G+ are markers used to define granulocytic MDSCs or neutrophils, and the latter popu-
lation is able to inhibit tumor growth by suppressing IL-17 expression at the early stage of  tumorigenesis 
(67). Furthermore, GM-CSF was reported to promote M1 macrophage polarization, which could also 
promote antitumor immunity (56, 68). However, increased infiltration of  NK and CD11b+Ly6G+(Gr-1+) 
cells in RaptorECKO tumors was not seen in the MMTV-PyMT-OVA model (Supplemental Figure 3D), 
suggesting that endothelial Raptor/mTORC1 has a diverse contribution to the TME depending on tumor 
type. Nevertheless, the mechanism of  the enhanced antitumor immune response in RaptorECKO tumors 
may involve multiple immune populations. Future work is needed to address the effect of  Raptor/
mTORC1 loss in endothelium on other immune cell populations.
Tumor immunotherapies have achieved dramatic success in clinical oncology. However, the majority 
of  patients do not respond to such treatments. Because antitumor clinical responses rely on T cells that 
recognize and kill cancer cells, recruitment of  such cancer-fighting T cells into the tumor parenchyma is 
paramount (69). Given the critical roles of  blood vessels in regulating leukocyte trafficking in normal tissue, 
one likely mechanism of  immune evasion is the abnormal tumor vasculature (4). Thus, normalization of  
tumor blood vessels holds the promise of  increasing TILs in “immune-excluded” tumors. The discovery 
that loss of  mTORC1 activity increases TILs opens up a new avenue of  driving T cells into the tumor 
parenchyma. mTORC1 inhibitors, such as RAD001/everolimus, are FDA-approved drugs, but at a thera-
peutic dose, rapalogs inhibit the immune system. However, at low doses (~100-fold lower than the doses 
approved for organ transplant and oncology patients), partial inhibition of  mTORC1 activity in clinical 
trials enhanced immune function and decreased infection rates in elderly patients (26, 27). Consistent with 
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clinical trial results, we have found that low-dose RAD001 induces normalization of  tumor blood vessels 
while increasing TILs (Figure 3 and Figure 4). Because RAD001 is a clinically approved drug, results from 
our studies can be quickly translated into clinical trials to improve both tumor sensitivity to immune check-
point inhibitors and adoptive T cell therapy.
Methods
Further information can be found in Supplemental Methods.
Mouse models. All mice used in this study were immunocompetent and housed in a nonbarrier animal facil-
ity. Raptorfl/fl (C57BL/6), MMTV-PyMT transgenic mammary tumor model (C57BL/6), OT-I (C57BL/6), 
OT-II (C57BL/6), CD45.1 (C57BL/6), and C57BL/6 mice were purchased from The Jackson Laborato-
ry. CDH5-CreERT2 mice (C57BL/6) were originally generated in Ralf  Adam’s laboratory (Max Planck 
Institute, Münster, Germany) and provided by Hong Chen (Boston Children’s Hospital, Harvard Medical 
School, Boston, Massachusetts, USA). Animals were genotyped for MMTV-PyMT, OT-I, OT-II, Cre, or 
floxed Raptor alleles using the primers listed in Supplemental Table 3. CD45.1+/+ alleles were confirmed by 
FACS analysis. To induce Raptor KO specifically in the endothelium, tamoxifen (T5648, MilliporeSigma) 
was reconstituted in sunflower seed oil (S5007, MilliporeSigma) at 15 mg/mL, and a dose of  2 mg/mouse 
was administered to 7-week-old mice by intraperitoneal injection for 5 consecutive days. The treated mice 
had a 1-week break before tumor implantation.
Tumor models and treatment regimens. The Lewis lung cancer–luciferase (LLC-Luc) tumor chunk (32) 
and MMTV-PyMT-OVA cell line were gifts from Chi-Ping Day and Glenn Merlino (National Cancer Insti-
tute at Frederick, Frederick, Maryland, USA) and from Washington University in St. Louis, respectively. 
The LLC-Luc tumor fragment was expanded subcutaneously in Raptorfl/fl mice for 4 passages before it 
was used for the experiment. To generate LLC-HRE-mCherry reporter cells, LLC parental cells, provided 
by Barbara Fingleton (Vanderbilt University), were infected with lentiviral HRE-mCherry and sorted for 
mCherry+ cells after culture under hypoxia conditions. The LLC-HRE-mCherry cells were further trans-
duced with viruses carrying pLVX-Hygro-IRES-OVA to generate the LLC-HRE-mCherry-OVA cell line. 
For the LLC allograft model, an LLC tumor chunk was cut into small pieces (~1 mm in diameter), and the 
fragments were implanted subcutaneously into the dorsal flanks of  recipient mice. For metastasis studies 
with size-matched primary tumors, the primary LLC tumors were surgically resected at 500 mm3, and 
the mice were kept for an additional 12 days to assess lung metastasis. For the orthotopic breast tumor 
model, MMTV-PyMT-OVA cells (~1 × 106 in 100 μL) were injected into the fourth mammary glands of  
female mice. Tumor volumes were measured at given time points. For the spontaneous breast tumor model, 
tamoxifen-treated female mice were assessed for tumor formation weekly by palpation beginning at 16 
weeks. Animals were sacrificed at 28 weeks before tumor burden reached humane endpoints. Tumor vol-
ume was calculated using the following formula: volume = length × width2 × 0.52. Lungs were harvested 
at the end of  the studies and surface metastatic lesions were quantified.
For GM-CSF depletion experiments, anti–GM-CSF neutralizing antibody (250 μg, clone MP1-22E9, cat-
alog BE0259, Bio X Cell) or anti–rat IgG2a isotype control (250 μg, clone 2A3, catalog BE0089, Bio X Cell) 
were injected intraperitoneally (i.p.) the day before (day –1) LLC tumor implantation, followed by injections 
on days +1 and +5 and every 5 days until tumors were harvested. For T cell depletion experiments, anti-CD4 
(clone GK1.5, catalog BE003-1, Bio X Cell), anti-CD8α (clone 53-6.7, catalog BE0004-1, Bio X Cell), a com-
bination of  anti-CD4 and anti-CD8α, or their corresponding isotype controls rat IgG2b (clone LTF-2, catalog 
BE0090, Bio X Cell) and rat IgG2a were injected (200 μg/animal, i.p.) on the day before (day –1) LLC tumor 
implantation and on days +4,+9, and +14 until tumors were harvested on day 18.
For mTORC1 inhibitor studies, LLC-HRE-mCherry-OVA cells (0.5 × 106 in 100 μL) were injected subcu-
taneously into C57BL/6 recipient mice. Six days after tumor implantation, mice were treated with RAD001/
everolimus at 0.01 mg/kg or 0.05 mg/kg or vehicle daily by i.p. injection for 8 days. On day 14, OVA peptide–
activated OT-I CD8+ and OT-II CD4+ T cells were adoptively transferred to tumor-bearing mice, and tumors 
were harvested on day 18. Three hours before harvesting, a hypoxic probe, EF5 (10 mM in 5% glucose, 200 
μL/mouse, University of  Pennsylvania, Philadelphia, Pennsylvania, USA, http://www.hypoxia-imaging.
org), was injected intravenously into the recipient mice for analysis of  hypoxia in the tumor.
Tumor hypoxia and blood vessel perfusion assay. To assess tumor hypoxia, 1 × 106 HRE-mCherry LLC cells 
were implanted subcutaneously into the dorsal flanks of  tamoxifen-treated mice. Tumor samples were har-
vested on day 16. CD31 staining on cryosections was performed as described in Supplemental Methods. 
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Hypoxia region was determined by assessing mCherry+ area per field in each tumor sample using ImageJ 
software (NIH). For vessel perfusion analysis, LLC tumor–bearing mice were injected intravenously with 
100 μL of  biotinylated Tomato Lectin (B1175, Vector Laboratories) 5 minutes before tumors were harvest-
ed and processed for CD31 staining. Streptavidin-conjugated Alexa Fluor 488 (S32354; Invitrogen, Ther-
mo Fisher Scientific) was used to detect Lectin+ vessels. The perfused area was defined as a percentage of  
Lectin+CD31+ of  the total CD31+ area using ImageJ.
Luminex assay and GM-CSF ELISA. After 7 days from the last tamoxifen treatment, LLC tumors were 
subcutaneously implanted into the treated mice and harvested on day 20. Tumor lysates were prepared 
using celLytic MT reagent (C3228, MilliporeSigma) with supplemental proteinase inhibitor cocktail 
(P8430, MilliporeSigma). Detection of  cytokines in tumor lysates was performed according to instruc-
tions using the Milliplex MAP mouse multiplex assay kit (MCYTMAG-70K-PX32, MilliporeSigma) and 
a FLEXMAP3D instrument (Luminex) as described before (70). Two quality control samples and 5 stan-
dards were run on the same plate to determine assay consistency and cytokine concentrations, respectively. 
Expression of  tested cytokines/chemokines in LLC WT and RaptorECKO tumors was normalized to protein 
concentrations and summarized in Supplemental Table 1. For GM-CSF ELISA, LLC tumors were harvest-
ed at day 20, and tumor lysates were prepared using celLytic MT reagent as described above. The level of  
GM-CSF in tumor samples was determined by using Mouse GM-CSF Quantikine ELISA kit (MGM00, 
R&D Systems, Bio-Techne) according to the manufacturer’s instructions.
Adoptive T cell transfer. To activate CD8+ T cells in vivo, NP16-OVA protein (1 mg/mL, N5051, Bio-
search Technologies) was injected with Alum adjuvant (77161, Thermo Fisher Scientific), at 1:1 ratio into 
10-week-old OT-I transgenic female mice (CD45.1) for 1 week. CD8+ T cells were isolated from spleens 
and lymph nodes of  immunized CD45.1 OT-I transgenic mice by negative selection using mouse CD8α+ 
T Cell Isolation Kit (130-104-075, Miltenyi Biotec). MMTV-PyMT-OVA tumor cells were implanted into 
female WT or RaptorECKO (CD45.2) recipients as described above and allowed to grow for 3 days. On 
day 4, mice were treated with tamoxifen for 5 consecutive days to deplete Raptor in ECs. On day 10, 3 × 
106 activated OT-I CD8+ T cells purified from CD45.1 donors were adoptively transferred into the WT 
or RaptorECKO tumor-bearing mice. Mice were sacrificed on day 14, and tumor-infiltrating immune cells 
were analyzed using flow cytometry, as described in Supplemental Methods. For RAD001/everolimus 
studies, splenocytes and lymph node cells were isolated from CD45.1 OT-I or CD45.1 OT-II mice and 
activated in vitro with OVA peptide SIINFEKL (1 μg/mL, vac-sin, InvivoGen) or peptide 323-339 (1 
μg/mL, RP1060, GenScript) with the presence of  IL-2 (20 U/mL, RO23-6019, Hoffmann-Roche) for 
48 hours. Activated OT-I CD8+ T cells were isolated by negative selection as described above. Activated 
OT-II CD4+ T cells were negatively selected by using a mixture of  anti-CD8 (130-117-044; Miltenyi 
Biotec) and anti-B220 (120-000-299; Miltenyi Biotec) microbeads. A combination of  purified CD8+ and 
CD4+ T cells (1 × 106 per population) was used for adoptive transfer.
Analysis of  single-cell RNA-Seq and TCGA data sets. Single-cell RNA-Seq data sets derived from TNBC 
(GSE18390) and NSCLC (GSE127465) patient studies (41, 42) were used for correlation analyses in ECs. 
ssGSEA was performed on previously identified ECs to calculate gene set enrichment scores using GSVA 
(v1.28.0) in R using single-cell expression matrix (71). The gene set containing PDGFB and TEK was 
defined as “vessel normalization signature” in this study based on their critical roles in pericyte recruitment 
(44). The gene sets of  “mTORC1-mediated signaling” and “Creighton_akt1 _signaling _via_mtor_dn” 
were chosen from REACTOME and chemical and genetic perturbations (72), respectively, under the C2 
collection of  Molecular Signatures Database and defined as “mTORC1 pathway genes” and “RAD001 
sensitive genes” here. Genes used in these sets to calculate enrichment scores are listed in Supplemental 
Table 2. The Pearson product moment correlation was performed to determine a linear association between 
mTORC1 activity and vessel normalization in ECs. The x and y axes represent ssGSEA enrichment scores 
of  indicated gene sets. Each data point represents a single EC.
TCGA BRCA database (data set ID: TCGA.BRCA.sampleMap/HiSeqV2, version 2017-10-13, n 
= 1218) and LUNG database (data set ID: TCGA.LUNG.sampleMap/HiSeqV2, version 2017-09-08, 
n = 1129) were used for correlation analysis between CSF-2 (GM-CSF) and immune cell markers in 
the context of  human tumors. Immune cytotoxic activity was calculated as an average expression of  3 
genes, IFNG, GZMB, and PRF1, similar to what was performed in several previous studies (45, 46). The 
abundance of  CD103+ DCs was determined by expression levels of  IRF8, Batf3, and Ccr7, 3 “signature 
genes” that were reported previously to indicate CD103+ DC population in human tumors (47, 48). 
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Scatterplots were generated using Prism to identify correlation profiles between log2(mRNA) expression 
of  GM-CSF and immune cell makers in tumor samples. Each data point represents a single patient. 
Linear regression and Pearson correlation were determined using GraphPad Prism software.
Statistics. All plots and statistical analysis were completed using GraphPad Prism software. For com-
parisons between 2 groups, unpaired 2-tailed Student’s t tests were performed as indicated. For multiple 
comparisons, 1- or 2-way ANOVA was performed with Tukey’s or Holm-Šidák multiple comparisons test. 
For comparison of  survival curves, log-rank (Mantel-Cox) test and Gehan-Breslow-Wilcoxon test were per-
formed. The heatmap was generated using Microsoft Excel software and displayed on a logarithmic scale 
with values normalized per row. Unless indicated in the figures, all data are presented as mean ± SD, and P 
< 0.05 was considered statistically significant.
Study approval. Animal care and experimental procedures were performed under protocols approved by 
Vanderbilt University’s IACUC.
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